MAIN CONTENT
A refusal centred on the size of the benefit
The FDA issued what Novocure described in a November 9 regulatory filing as a Not Approvable Letter concerning the premarket approval application for Optune Mya. The proposed indication was specific: adults with brain metastases from non-small cell lung cancer who had already received stereotactic radiation. The agency was not passing judgment on every application of the company's tumour-treating fields platform, nor announcing a general withdrawal of an existing treatment.
Novocure said regulators were uncertain about the degree of clinical benefit the device would deliver. That is materially different from saying the treatment is proven ineffective. It also does not mean the submission met the evidentiary threshold required for marketing the device to this population. The company's account of the FDA response expressly said there were no concerns raised about the product's safety profile.
The company is studying the feedback and seeking a meeting with regulators. It hopes to learn whether a path to approval might be available without additional clinical trials. But Novocure also cautioned that neither those discussions nor a future submission guarantees approval. The next milestone is therefore regulatory clarity, not a scheduled commercial launch.














